This company listing is no longer active
Spectrum Pharmaceuticals Management
Management criteria checks 1/4
Spectrum Pharmaceuticals' CEO is Tom Riga, appointed in Dec 2021, he has a tenure of 1.67 years. His total yearly compensation is $2.60M , comprised of 25% salary and 75% bonuses, including company stock and options. He directly owns 0.26% of the company’s shares, worth €489.48K. The average tenure of the management team and the board of directors is 1.5 years and 2.5 years respectively.
Key information
Tom Riga
Chief executive officer
US$2.6m
Total compensation
CEO salary percentage | 25.0% |
CEO tenure | 1.7yrs |
CEO ownership | 0.3% |
Management average tenure | 1.5yrs |
Board average tenure | 2.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Mar 31 2023 | n/a | n/a | -US$68m |
Dec 31 2022 | US$3m | US$650k | -US$78m |
Sep 30 2022 | n/a | n/a | -US$106m |
Jun 30 2022 | n/a | n/a | -US$117m |
Mar 31 2022 | n/a | n/a | -US$138m |
Dec 31 2021 | US$4m | US$550k | -US$158m |
Sep 30 2021 | n/a | n/a | -US$169m |
Jun 30 2021 | n/a | n/a | -US$184m |
Mar 31 2021 | n/a | n/a | -US$166m |
Dec 31 2020 | US$3m | US$550k | -US$171m |
Sep 30 2020 | n/a | n/a | -US$162m |
Jun 30 2020 | n/a | n/a | -US$140m |
Mar 31 2020 | n/a | n/a | -US$136m |
Dec 31 2019 | US$4m | US$550k | -US$135m |
Sep 30 2019 | n/a | n/a | -US$148m |
Jun 30 2019 | n/a | n/a | -US$191m |
Mar 31 2019 | n/a | n/a | -US$147m |
Dec 31 2018 | US$5m | US$500k | -US$127m |
Sep 30 2018 | n/a | n/a | -US$102m |
Jun 30 2018 | n/a | n/a | -US$51m |
Mar 31 2018 | n/a | n/a | -US$87m |
Dec 31 2017 | US$1m | US$420k | -US$101m |
Compensation vs Market: Tom's total compensation ($USD2.60M) is above average for companies of similar size in the German market ($USD684.36K).
Compensation vs Earnings: Tom's compensation has been consistent with company performance over the past year.
CEO
Tom Riga (48 yo)
1.7yrs
Tenure
US$2,595,633
Compensation
Mr. Thomas J. Riga, also known as Tom, is President, Chief Executive Officer and Director at Spectrum Pharmaceuticals, Inc. since December 30, 2021. He had been the Chief Operating Officer at Spectrum Phar...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 1.7yrs | US$2.60m | 0.26% € 489.5k | |
Executive VP & CFO | 1.3yrs | US$46.25k | 0.051% € 98.3k | |
Executive VP | 5.5yrs | US$1.50m | 0.11% € 217.8k | |
Executive VP & Chief Business Officer | less than a year | no data | no data |
1.5yrs
Average Tenure
48yo
Average Age
Experienced Management: NTR's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 1.7yrs | US$2.60m | 0.26% € 489.5k | |
Independent Director | 3.3yrs | US$178.83k | 0.0020% € 3.8k | |
Independent Chairman of the Board | 5.5yrs | US$202.58k | 0.021% € 40.0k | |
Independent Director | 4.8yrs | US$181.33k | 0.13% € 253.4k | |
Independent Director | 1.3yrs | US$158.53k | no data | |
Director | 1.4yrs | US$183.93k | 0.0023% € 4.5k |
2.5yrs
Average Tenure
53.5yo
Average Age
Experienced Board: NTR's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.